ES2169723T3 - Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales. - Google Patents

Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales.

Info

Publication number
ES2169723T3
ES2169723T3 ES93810049T ES93810049T ES2169723T3 ES 2169723 T3 ES2169723 T3 ES 2169723T3 ES 93810049 T ES93810049 T ES 93810049T ES 93810049 T ES93810049 T ES 93810049T ES 2169723 T3 ES2169723 T3 ES 2169723T3
Authority
ES
Spain
Prior art keywords
derivatives
connective tissue
piridiny
human
tissue disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93810049T
Other languages
English (en)
Inventor
Laszlo Revesz
Rudolf Waelchli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2169723T3 publication Critical patent/ES2169723T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Soft Magnetic Materials (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCESO PARA LA PRODUCCION DE ENLACES CRUZADOS DE PIRIDINOLINA Y DEOXIPIRIDINOLINA Y SUS DERIVADOS DE LA FORMULA (I) EN LA QUE X, Y, Z, R1, R2, R3, R4, X1 Y X2 TIENEN LOS SIGNIFICADOS QUE SE DAN EN LA DESCRIPCION Y SU USO EN LA DETERMINACION DE ENFERMEDADES DE TEJIDOS CONJUNTIVOS EN PERSONAS Y ANIMALES.
ES93810049T 1992-01-31 1993-01-26 Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales. Expired - Lifetime ES2169723T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929202139A GB9202139D0 (en) 1992-01-31 1992-01-31 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
ES2169723T3 true ES2169723T3 (es) 2002-07-16

Family

ID=10709643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93810049T Expired - Lifetime ES2169723T3 (es) 1992-01-31 1993-01-26 Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales.

Country Status (16)

Country Link
EP (1) EP0556152B1 (es)
JP (1) JP3544549B2 (es)
AT (1) ATE210645T1 (es)
AU (1) AU663909B2 (es)
CA (1) CA2088396A1 (es)
CZ (1) CZ288038B6 (es)
DE (1) DE69331293T2 (es)
DK (1) DK0556152T3 (es)
ES (1) ES2169723T3 (es)
FI (1) FI104896B (es)
GB (1) GB9202139D0 (es)
HU (1) HU214677B (es)
NO (1) NO180779C (es)
PT (1) PT556152E (es)
SG (1) SG43065A1 (es)
SK (1) SK281137B6 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620861A (en) * 1992-07-31 1997-04-15 Metra Biosystems, Inc. Method and kit for pyridinium crosslink assay
US5756361A (en) * 1992-12-17 1998-05-26 Metra Biosystems, Inc. Screening method for periodontal disease
US5736344A (en) * 1992-12-17 1998-04-07 Metra Biosystems, Inc. Serum pyridinium crosslinks assay
US5661039A (en) * 1995-03-01 1997-08-26 Metra Biosystems, Inc. Perspiration assay for bone resorption
US5723619A (en) * 1997-01-13 1998-03-03 Bayer Corporation Method for the synthesis of deoxypyridinoline
US5834610A (en) * 1997-05-06 1998-11-10 Johnson; Gary M. Conversion of pyridinoline to deoxypyridinoline
CN105801688A (zh) * 2016-04-14 2016-07-27 苏州博源医疗科技有限公司 脱氧吡啶酚免疫原、抗体和检测试剂及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148766A (ja) * 1983-02-10 1984-08-25 Otsuka Pharmaceut Co Ltd ピリジン誘導体
US4973666A (en) * 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
GB8929366D0 (en) * 1989-12-30 1990-02-28 Rowett Research Inst Method to detect connective tissue disorder in humans and animals

Also Published As

Publication number Publication date
AU663909B2 (en) 1995-10-26
JPH0641078A (ja) 1994-02-15
SK281137B6 (sk) 2000-12-11
NO180779B (no) 1997-03-10
AU3210593A (en) 1993-08-05
DE69331293D1 (de) 2002-01-24
GB9202139D0 (en) 1992-03-18
HU9300108D0 (en) 1993-04-28
HU214677B (hu) 1998-04-28
DK0556152T3 (da) 2002-04-08
NO180779C (no) 1997-06-18
CA2088396A1 (en) 1993-08-01
EP0556152A1 (en) 1993-08-18
PT556152E (pt) 2002-05-31
HUT70276A (en) 1995-09-28
CZ288038B6 (cs) 2001-04-11
SG43065A1 (en) 1997-10-17
FI930367A (fi) 1993-08-01
FI930367A0 (fi) 1993-01-28
ATE210645T1 (de) 2001-12-15
FI104896B (fi) 2000-04-28
JP3544549B2 (ja) 2004-07-21
EP0556152B1 (en) 2001-12-12
NO930284L (no) 1993-08-02
DE69331293T2 (de) 2002-07-18
NO930284D0 (no) 1993-01-28
SK4293A3 (en) 1993-11-10
CZ10693A3 (en) 1993-12-15

Similar Documents

Publication Publication Date Title
PT1254899E (pt) Derivados de piperazina e sua utilizacao como agentes anti-inflamatorios
PT97890A (pt) Processo para a preparacao de ftalidas substituidas e de ftalidas heterociclicas
PT99400A (pt) Processo para a preparacao de derivados de 3-amido- e 3-sulfamido-indolilo e de composicoes farmaceuticas que os contem
ES2133430T3 (es) Derivados de n-heteroaril-n-fenilurea, su preparacion y utilizacion.
FI935360A (fi) Guanidiinialkyyli-1,1-bifosfonihappojohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö
EA200200520A1 (ru) Производные гетероциклоалкилсульфонилпиразола в качестве противовоспалительных/анальгетических агентов
ES2169723T3 (es) Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales.
ES2116496T3 (es) Proceso para la preparacion de 1,4-disubstituido-5(4h)-tetrazolinonas.
BR9815919A (pt) Compostos aza heterocìclicos usados para tratar distúrbios neurológicos e perda de cabelo
DK0501378T3 (da) NMDA-antagonister
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
ES2128335T3 (es) Derivados de imidazo(1,2-c)quinazolina como antihipertensivos y antidisuricos.
ES2082882T3 (es) Procedimiento para la fabricacion de derivados de acidos-3-amino-2-(het)aroil-acrilicos.
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
ES2149850T3 (es) Utilizacion de la selegilina en medicina veterinaria.
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE112284T1 (de) Exo-3'-4'-o-benzyliden-3''-demethylchartreusin und seine salze.
ES2059055T3 (es) Quitaesmalte de uñas.
ATE142220T1 (de) Antagonisten reizübertragender aminosäuren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556152

Country of ref document: ES